Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov.
Most participants first33,758 with no events in either group come last2,701 to 2,720 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Folic Acid 4 mg vs Placebo: Composite Severe Adverse Fetal/Neonatal Outcome | 63 of 1,349 51 of 1,348 | 0.9 points -0.6 to 2.4 | 2,697 | NCT01355159 High Dose Folic Acid Supplementation Throughout Pregnancy for Preeclampsia Prevention |
| Phase 3 Cohort 1 (2.4g IV) >= 18 vs Phase 3 Cohort 1 (Placebo) >=18: Proportion of Participants With ≥1 COVID-19-related Hospitalization, Emergency Room Visit, or All-cause Death (Ph3 Cohort 1) - Placebo vs. 2.4g IV | 18 of 1,355 62 of 1,341 | -3.3 points -4.6 to -2.0 | 2,696 | NCT04425629 Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Adult and Pediatric Patients With COVID-19 |
| Folic Acid 4 mg vs Placebo: Intrauterine Growth Restriction (<10th Percentile) | 151 of 1,347 144 of 1,348 | 0.5 points -1.8 to 2.9 | 2,695 | NCT01355159 High Dose Folic Acid Supplementation Throughout Pregnancy for Preeclampsia Prevention |
| Folic Acid 4 mg vs Placebo: Intrauterine Growth Restriction (<3rd Percentile) | 20 of 1,347 25 of 1,348 | -0.4 points -1.4 to 0.6 | 2,695 | NCT01355159 High Dose Folic Acid Supplementation Throughout Pregnancy for Preeclampsia Prevention |
| Folic Acid 4 mg vs Placebo: Neonatal Intensive Care Unit (NICU) Admission | 299 of 1,346 267 of 1,348 | 2.4 points -0.7 to 5.5 | 2,694 | NCT01355159 High Dose Folic Acid Supplementation Throughout Pregnancy for Preeclampsia Prevention |
| Folic Acid 4 mg vs Placebo: Ventilation | 49 of 1,346 30 of 1,348 | 1.4 points 0.1 to 2.7 | 2,694 | NCT01355159 High Dose Folic Acid Supplementation Throughout Pregnancy for Preeclampsia Prevention |
| Treatment - Participation in Nurse Family Partnership vs Control: Number of Participants With a Group B Streptococcus Test (35-37 Weeks) | 1,150 of 1,807 602 of 885 | -4.4 points -8.1 to -0.6 | 2,692 | NCT03360539 Nurse-Family Partnership Impact Evaluation in South Carolina |
| Phase 3 Cohort 1 (2.4g IV) >= 18 vs Phase 3 Cohort 1 (Placebo) >=18: Proportion of Participants With ≥1 COVID-19-related Hospitalization or All-cause Death From Day 4 Through Day 29 (Ph3 Cohort 1 - 2.4g vs. Placebo) | 5 of 1,351 46 of 1,340 | -3.1 points -4.2 to -2.1 | 2,691 | NCT04425629 Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Adult and Pediatric Patients With COVID-19 |
| Folic Acid 4 mg vs Placebo: Necrotising Enterocolitis | 8 of 1,343 3 of 1,347 | 0.4 points -0.1 to 1.0 | 2,690 | NCT01355159 High Dose Folic Acid Supplementation Throughout Pregnancy for Preeclampsia Prevention |
| Folic Acid 4 mg vs Placebo: Neonatal Death | 8 of 1,343 11 of 1,347 | -0.2 points -0.9 to 0.5 | 2,690 | NCT01355159 High Dose Folic Acid Supplementation Throughout Pregnancy for Preeclampsia Prevention |
| Folic Acid 4 mg vs Placebo: Intraventricular Hemorrhage (IVH) | 18 of 1,343 19 of 1,347 | -0.1 points -1.0 to 0.8 | 2,690 | NCT01355159 High Dose Folic Acid Supplementation Throughout Pregnancy for Preeclampsia Prevention |
| Folic Acid 4 mg vs Placebo: Neonatal Death | 151 of 1,343 144 of 1,347 | 0.6 points -1.8 to 2.9 | 2,690 | NCT01355159 High Dose Folic Acid Supplementation Throughout Pregnancy for Preeclampsia Prevention |
| Folic Acid 4 mg vs Placebo: Periventricular Leukomalacia | 4 of 1,343 2 of 1,347 | 0.1 points -0.3 to 0.6 | 2,690 | NCT01355159 High Dose Folic Acid Supplementation Throughout Pregnancy for Preeclampsia Prevention |
| SZC (Active) vs Placebo: Incidence of the Composite of Cardiac Event Outcomes | 119 of 1,349 119 of 1,341 | -0.1 points -2.2 to 2.1 | 2,690 | NCT04847232 Effect of Sodium Zirconium Cyclosilicate on Arrythmia-related Cardiovascular Outcomes in Participants on Chronic Hemodialysis With Recurrent Hyperkalemia (DIALIZE-Outcomes) |
| SZC (Active) vs Placebo: Incidence of the Composite of Arrhythmia Related Events | 74 of 1,349 65 of 1,341 | 0.6 points -1.0 to 2.3 | 2,690 | NCT04847232 Effect of Sodium Zirconium Cyclosilicate on Arrythmia-related Cardiovascular Outcomes in Participants on Chronic Hemodialysis With Recurrent Hyperkalemia (DIALIZE-Outcomes) |
| Folic Acid 4 mg vs Placebo: Retinopathy of Prematurity | 21 of 1,342 13 of 1,347 | 0.6 points -0.3 to 1.5 | 2,689 | NCT01355159 High Dose Folic Acid Supplementation Throughout Pregnancy for Preeclampsia Prevention |
| Folic Acid 4 mg vs Placebo: Early Onset Sepsis | 3 of 1,342 9 of 1,347 | -0.4 points -1.1 to 0.1 | 2,689 | NCT01355159 High Dose Folic Acid Supplementation Throughout Pregnancy for Preeclampsia Prevention |
| Adriamycin + Cyclophosphamide vs Fluorouracil + Epirubicin + Cyclophosphamide: serious adverse events | 12 of 1,351 26 of 1,337 | -1.1 points -2.0 to -0.2 | 2,688 | NCT00087178 Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer |
| SZC (Active) vs Placebo: deaths from any cause | 120 of 1,348 113 of 1,338 | 0.5 points -1.7 to 2.6 | 2,686 | NCT04847232 Effect of Sodium Zirconium Cyclosilicate on Arrythmia-related Cardiovascular Outcomes in Participants on Chronic Hemodialysis With Recurrent Hyperkalemia (DIALIZE-Outcomes) |
| SZC (Active) vs Placebo: serious adverse events | 521 of 1,348 503 of 1,338 | 1.1 points -2.6 to 4.7 | 2,686 | NCT04847232 Effect of Sodium Zirconium Cyclosilicate on Arrythmia-related Cardiovascular Outcomes in Participants on Chronic Hemodialysis With Recurrent Hyperkalemia (DIALIZE-Outcomes) |
Code
curl "https://conductscience.org/api/comparisons/v1?page=136"
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=136
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT01355159-5e71a335",
"title": "Folic Acid 4 mg vs Placebo: Composite Severe Adverse Fetal/Neonatal Outcome",
"summary": "63 of 1349 against 51 of 1348; risk difference 0.9 points, 95% interval -0.6 to 2.4; NCT01355159, High Dose Folic Acid Supplementation Throughout Pregnancy for Preeclampsia Prevention",
"record": "/library/comparisons/NCT01355159-5e71a335",
"nct_id": "NCT01355159",
"kind": "outcome",
"participants": 2697,
"risk_difference": {
"value": 0.00886743229956028,
"lower": -0.0064435535827067954,
"upper": 0.024321257737997762
},
"group_1": "63 of 1,349",
"group_2": "51 of 1,348",
"difference": "0.9 points",
"interval": "-0.6 to 2.4",
"trial_title": "High Dose Folic Acid Supplementation Throughout Pregnancy for Preeclampsia Prevention"
},
{
"id": "NCT04425629-eae26900",
"title": "Phase 3 Cohort 1 (2.4g IV) >= 18 vs Phase 3 Cohort 1 (Placebo) >=18: Proportion of Participants With ≥1 COVID-19-related Hospitalization, Emergency Room Visit, or All-cause Death (Ph3 Cohort 1) - Placebo vs. 2.4g IV",
"summary": "18 of 1355 against 62 of 1341; risk difference -3.3 points, 95% interval -4.6 to -2.0; NCT04425629, Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Adult and Pediatric Patients With COVID-19",
"record": "/library/comparisons/NCT04425629-eae26900",
"nct_id": "NCT04425629",
"kind": "outcome",
"participants": 2696,
"risk_difference": {
"value": -0.03295002077537554,
"lower": -0.046450914504385335,
"upper": -0.020378297111250242
},
"group_1": "18 of 1,355",
"group_2": "62 of 1,341",
"difference": "-3.3 points",
"interval": "-4.6 to -2.0",
"trial_title": "Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Adult and Pediatric Patients With COVID-19"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=137",
"request_id": "sTdyRE9Rt2tqcrrJ"
}Ask about these results. The first 10 go in the prompt.
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant